Amphastar Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Amphastar Pharmaceuticals (Rancho Cucamonga, CA): 5 reconciled FDA prescription therapies (0.0% 2025 to 2030 cliff risk), $121.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterRancho Cucamonga, CA
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$121.5M
2024 Medicare Part D Spend$40.5M
2024 Medicaid Spend$81.0M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel